Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

[1]  M. Kanda,et al.  Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico‐pathological parameters , 2008, Journal of surgical oncology.

[2]  Sheung Tat Fan,et al.  Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. , 2008, Journal of the American College of Surgeons.

[3]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[4]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[5]  M. Ho,et al.  Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. , 2007, Cancer letters.

[6]  Thomas A Trikalinos,et al.  The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey , 2007, Canadian Medical Association Journal.

[7]  S. Fan,et al.  High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies , 2007, Annals of Surgical Oncology.

[8]  A. Dennison,et al.  Prognostic molecular markers in hepatocellular carcinoma: a systematic review. , 2007, European journal of cancer.

[9]  Ning Zhang,et al.  Factors predictive for long‐term survival of male patients with hepatocellular carcinoma after curative resection , 2007, Journal of surgical oncology.

[10]  J. Ioannidis,et al.  Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. , 2007, Journal of the National Cancer Institute.

[11]  R. Poon,et al.  Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. , 2006, Cancer letters.

[12]  S. Ferrero,et al.  Differences between plasma and serum vascular endothelial growth factor. , 2006, The American journal of cardiology.

[13]  P. Malfertheiner,et al.  Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma , 2006, Journal of Cancer Research and Clinical Oncology.

[14]  J. Xu,et al.  CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients , 2006, Cancer biology & therapy.

[15]  Wei Wei,et al.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma , 2006, Journal of Cancer Research and Clinical Oncology.

[16]  Y. Takeda,et al.  Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin‐2 and hypoxia‐induced factor‐1a , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[17]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[18]  M. Makuuchi,et al.  Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. , 2005, World journal of gastroenterology.

[19]  I. Sheen,et al.  Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[20]  S. Fan,et al.  Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma , 2004, The British journal of surgery.

[21]  S. Fan,et al.  High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. , 2004, Oncology reports.

[22]  S. Oh,et al.  Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. , 2004, Japanese journal of clinical oncology.

[23]  I. Sheen,et al.  Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. , 2004, World journal of gastroenterology.

[24]  I. Sheen,et al.  Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? , 2004, World journal of gastroenterology.

[25]  Zhao-You Tang,et al.  Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives , 2004, Journal of Cancer Research and Clinical Oncology.

[26]  L. Ellis,et al.  Comparison of Clinicopathologic Characteristics and Outcomes After Resection in Patients With Hepatocellular Carcinoma Treated in the United States, France, and Japan , 2003, Annals of surgery.

[27]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[28]  S. Cheung,et al.  Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. , 2003, Cancer research.

[29]  Chih-Ping Chen,et al.  Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery , 2003, Annals of Surgical Oncology.

[30]  H. El‐Serag.  Hepatocellular carcinoma: an epidemiologic view. , 2002, Journal of clinical gastroenterology.

[31]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[32]  S. Fan,et al.  Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study , 2001, Annals of surgery.

[33]  G. Chau,et al.  Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. , 2000, Surgery.

[34]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[35]  M. Bottomley,et al.  Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. , 1998, Clinical science.

[36]  S. Ye,et al.  Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. , 1998, Journal of experimental & clinical cancer research : CR.

[37]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[38]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[39]  I. Su,et al.  Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. , 1997, Human pathology.

[40]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[41]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[42]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .